Opinion and observations from life risk industry insiders, academics and policy makers
The climate crisis has both direct and indirect impacts on human health, and we stand at a dire crossroads in terms of human health
Prudent Due Diligence Key to Mitigating Life Settlement Unlicensed Operator Risk
What should institutional investors – both those already allocating capital to an existing fund, or those looking to do so for the first time – be considering here?
Stuart McDonald discusses the impact of the Covid-19 pandemic on pension scheme mortality in the United Kingdom
Caveat Emptor: Life Settlements and the Natural Person Exemption From Licensure
James W. Maxson explains the nuances of the “natural person” exemption from licensure to purchase life insurance policies
Actuarial Risk Management’s Cory Zass looks at what 2023 might have in store for the life settlement market
Celent’s Rob Norris offers his views on terminology in the insurtech market and what he real technology to emphasise is
In the past 40 years, life expectancy has increased significantly as a result of a range of factors, including advancements in cardiovascular treatments and reduction in smoking prevalence. Looking forward, what will drive future longevity trends?
Life Settlements Portfolio Construction – Art or Science?
The dimensions of life settlements – life expectancy, age of insured, gender, projected premium streams – are unlike any other asset, so constructing a life settlement portfolio comes with a different set of challenges than other asset classes
The realisation that machine learning could be useful in prequal came around 2016 when carriers started to increase cost of insurance rates
Like many things in life, longevity markets have followed broad cycles. Industry veterans will remember a particularly painful turn in…